
Renting the Molecule Factory: Pierre Fabre, XtalPi and Mid-Sized Pharma's AI Bet
Dr. Dereck Mush, MD, MBANovartis is a Swiss pharmaceutical company that develops patented medicines across four core therapeutic areas.
Novartis was formed in 1996 through the merger of two Basel drug makers and is headquartered in Basel. After spinning off its generics and biosimilars business, Sandoz, in October 2023, it concentrates on patented prescription medicines. Its four core therapeutic areas are cardiovascular, renal, and metabolic disease; immunology; neuroscience; and oncology. Novartis also invests in newer technology platforms, including radioligand therapy, which uses targeted radiation to treat cancer. It sells to health systems, payers, and prescribing physicians worldwide.
Leadership as of 14 November 2026.
Chief Executive Officer

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBAMentions Novartis

Dr. Dereck Mush, MD, MBAMentions Novartis
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: